bluuebunny/crossref_metadata_2025 huggingface dataset:
Suppl Fig.1 from Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
Authors: Canale Matteo , Petracci Elisabetta , Delmonte Angelo , Chiadini Elisa , Dazzi Claudio , Papi Maximilian , Capelli Laura , Casanova Claudia , De Luigi Nicoletta , Mariotti Marita , Gamboni Alessandro , Chiari Rita , Bennati Chiara , Calistri Daniele , Ludovini Vienna , Crinò Lucio , Amadori Dino , Ulivi Paola
Published: April 2023

Supplementary Figure 1. a) PFS and b) OS of TP53 exon 8 mutated patients, other TP53 non-disruptive mutated patients and TP53 wt/disruptive mutated patients in the overall case series. c) PFS and d) OS of TP53 exon 8 mutated patients, other TP53 non-disruptive mutated patients and TP53 wt/disruptive mutated patients in the subgroup of patients with EGFR exon 19 deletion. NR=not reached.
Supplemental Table 2 from The RARS–MAD1L1 Fusion Gene Induces Cancer Stem Cell–like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma
Authors: Zhong Qian , Liu Zhi-Hua , Lin Zhi-Rui , Hu Ze-Dong , Yuan Li , Liu Yan-min , Zhou Ai-Jun , Xu Li-Hua , Hu Li-Juan , Wang Zi-Feng , Guan Xin-Yuan , Hao Jia-Jie , Lui Vivian W.Y. , Guo Ling , Mai Hai-Qiang , Chen Ming-Yuan , Han Fei , Xia Yun-Fei , Grandis Jennifer R. , Zhang Xing , Zeng Mu-Sheng
Published: April 2023

Cell Line authentication
Supplementary Figure 2 from BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection—Implications for Oncolytic Viral Therapy
Authors: Bolyard Chelsea , Meisen W. Hans , Banasavadi-Siddegowda Yeshavanth , Hardcastle Jayson , Yoo Ji Young , Wohleb Eric S. , Wojton Jeffrey , Yu Jun-Ge , Dubin Samuel , Khosla Maninder , Xu Bo , Smith Jonathan , Alvarez-Breckenridge Christopher , Pow-anpongkul Pete , Pichiorri Flavia , Zhang Jianying , Old Matthew , Zhu Dan , Van Meir Erwin G. , Godbout Jonathan P. , Caligiuri Michael A. , Yu Jianhua , Kaur Balveen
Published: April 2023

Co-culture model of endogenous Vstat120 impact on microglia response to oHSV-infected glioma.
Supplementary Figure S1 from Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo
Authors: Laszlo Viktoria , Valko Zsuzsanna , Kovacs Ildiko , Ozsvar Judit , Hoda Mir Alireza , Klikovits Thomas , Lakatos Dora , Czirok Andras , Garay Tamas , Stiglbauer Alexander , Helbich Thomas H. , Gröger Marion , Tovari Jozsef , Klepetko Walter , Pirker Christine , Grusch Michael , Berger Walter , Hilberg Frank , Hegedus Balazs , Dome Balazs
Published: April 2023

Expression of PDGFRB and FGFR1 in MPM cell lines with different histological origin
Table S6 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Authors: Fu Hangcheng , Zhu Yu , Wang Yiwei , Liu Zheng , Zhang Junyu , Xie Huyang , Fu Qiang , Dai Bo , Ye Dingwei , Xu Jiejie
Published: April 2023

Correlation between immune phenotypes and immune check point molecule expression with TCGA cohort
Supplemental Table S1 from Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population
Authors: Hart Christopher D. , Vignoli Alessia , Tenori Leonardo , Uy Gemma Leonora , Van To Ta , Adebamowo Clement , Hossain Syed Mozammel , Biganzoli Laura , Risi Emanuela , Love Richard R. , Luchinat Claudio , Di Leo Angelo
Published: April 2023

Comparison of individual metabolite concentrations in arbitrary units in the serum NMR spectra of EBC and MBC patients, for a single centre (Philippines General Hospital - PGH). Adjusted P-values are for the significance of any difference between EBC and MBC. MAD = median absolute deviation.
Table S3 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Authors: Fu Hangcheng , Zhu Yu , Wang Yiwei , Liu Zheng , Zhang Junyu , Xie Huyang , Fu Qiang , Dai Bo , Ye Dingwei , Xu Jiejie
Published: April 2023

Univariable Cox Regression Analysis of 10 Immune Phenotypes and Overall Survival in the Training Cohort, Testing Cohort
Table S2 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Authors: Fu Hangcheng , Zhu Yu , Wang Yiwei , Liu Zheng , Zhang Junyu , Xie Huyang , Fu Qiang , Dai Bo , Ye Dingwei , Xu Jiejie
Published: April 2023

Antibody sources and staining conditions
Suppl Table 6 from The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA
Authors: Parpart-Li Sonya , Bartlett Bjarne , Popoli Maria , Adleff Vilmos , Tucker Laura , Steinberg Rebecca , Georgiadis Andrew , Phallen Jill , Brahmer Julie , Azad Nilo , Browner Ilene , Laheru Daniel , Velculescu Victor E. , Sausen Mark , Diaz Luis A.
Published: April 2023

Average DNA Yield and Range of Plasma Isolated in Healthy Donors vs. Diseased Donors
Supplementary Figure 1 from Survival and Proliferation of Neural Progenitor–Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism
Authors: Calinescu Anda-Alexandra , Yadav Viveka Nand , Carballo Erica , Kadiyala Padma , Tran Dustin , Zamler Daniel B. , Doherty Robert , Srikanth Maithreyi , Lowenstein Pedro Ricardo , Castro Maria Graciela
Published: April 2023

At 19 days after injection tumor cells induced with NRAS and SV40 LgT express markers characteristic of NPCs and GSLCs: Nestin, GFAP and Olig2.
Supplementary Tables and Figures from Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)
Authors: Butterfield Lisa H. , Zhao Fengmin , Lee Sandra , Tarhini Ahmad A. , Margolin Kim A. , White Richard L. , Atkins Michael B. , Cohen Gary I. , Whiteside Theresa L. , Kirkwood John M. , Lawson David H.
Published: April 2023

Supplementary Tables S1 through S3 Supplementary Figures S1 through S3
Godse et al - Supplementary Data from TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression
Authors: Godse Neal R. , Khan Nayel , Yochum Zachary A. , Gomez-Casal Roberto , Kemp Carolyn , Shiwarski Daniel J. , Seethala Raja S. , Kulich Scott , Seshadri Mukund , Burns Timothy F. , Duvvuri Umamaheswar
Published: April 2023

Supplemental packet contains supplemental figures for "TMEM16A/ANO1 overexpression inhibits apoptosis via down-regulation of Bim expression." It also contains uncropped blots corresponding to blots in the main and supplemental figures. Uncropped blots are labeled & grouped by figure and panel in which the cropped version of the blots are used.
Supplementary Figure 6 from The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB
Authors: Garcia-Heredia Jose Manuel , Lucena-Cacace Antonio , Verdugo-Sivianes Eva M. , Pérez Marco , Carnero Amancio
Published: April 2023

Supplementary Figure 6. Stem cell related genes correlated with MAP17. Red color indicated positive correlations; blue color, negative correlations. Lung: P: Peitsch; Bi: Bild; E: EXPO; M: Muley; Ta: TCGA515; Tb: TCGA81; Cervix: Tc: TCGA305; A: Ahlquist; Breast: Bo: Bos; Eb: EXPO; I: Iglehart; Mi: Miller; S: Servant; So: Sotiriou; W: Wang; Td: TCGA1097; Te: TCGA528; H: Halfwerk; Colon: Ec: EXPO; O: Olschwang; Si: Sieber; Sm: Smith; D: Domany; C: Clary; Tf: TCGA286; Bu: Budinska; J: Jorissen; Ma: Marissa.
Supplementary Figure 3 from The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB
Authors: Garcia-Heredia Jose Manuel , Lucena-Cacace Antonio , Verdugo-Sivianes Eva M. , Pérez Marco , Carnero Amancio
Published: April 2023

Supplementary Figure 3. HeLa cells cultured for 15 days in soft-agar, showing number and size of HeLa colonies. The graphs show the average of 3 independent experiments performed in triplicate. Student's T test statistical analysis of the data was performed to find statistical differences (**=p<0.01; ***=p<0.001).
Supplementary Figure S1 from Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma
Authors: Chudasama Priya , Renner Marcus , Straub Melanie , Mughal Sadaf S. , Hutter Barbara , Kosaloglu Zeynep , Schweßinger Ron , Scheffler Matthias , Alldinger Ingo , Schimmack Simon , Persigehl Thorsten , Kobe Carsten , Jäger Dirk , von Kalle Christof , Schirmacher Peter , Beckhaus Marie-Kristin , Wolf Stephan , Heining Christoph , Gröschel Stefan , Wolf Jürgen , Brors Benedikt , Weichert Wilko , Glimm Hanno , Scholl Claudia , Mechtersheimer Gunhild , Specht Katja , Fröhling Stefan
Published: April 2023

Proportion of FGFR1-altered cases among different STS subtypes.
Supplementary data [S-4] from Prebiopsy mp-MRI Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients
Authors: Wang Rui , Wang Jing , Gao Ge , Hu Juan , Jiang Yuanyuan , Zhao Zhenlong , Zhang Xiaodong , Zhang Yu-Dong , Wang Xiaoying
Published: April 2023

workflow of machine learning analysis using support vector machine for model development in 985 training data. FDR = false discovery rate; PCA = principal component analysis.
Supplementary figure 1 from Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Authors: Wang Chun-Meng , Wu Zhi-Qiang , Wang Yao , Guo Ye-Lei , Dai Han-Ren , Wang Xiao-Hui , Li Xiang , Zhang Ya-Jing , Zhang Wen-Ying , Chen Mei-Xia , Zhang Yan , Feng Kai-Chao , Liu Yang , Li Su-Xia , Yang Qing-Ming , Han Wei-Dong
Published: April 2023

The change of cytokine levels within three months after CART-30 cell infusion.
Supplementary data [S-1] from Prebiopsy mp-MRI Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients
Authors: Wang Rui , Wang Jing , Gao Ge , Hu Juan , Jiang Yuanyuan , Zhao Zhenlong , Zhang Xiaodong , Zhang Yu-Dong , Wang Xiaoying
Published: April 2023

the prostate MR imaging parameters at 1.5 T MR
Supplementary figure and table legends from A Threshold of Systemic MAGE-A Gene Expression Predicting Survival in Resected Non–Small Cell Lung Cancer
Authors: Mecklenburg Ingo , Sienel Wulf , Schmid Severin , Passlick Bernward , Kufer Peter
Published: April 2023

Supplementary figures and table legend
Figure S2 from A Threshold of Systemic MAGE-A Gene Expression Predicting Survival in Resected Non–Small Cell Lung Cancer
Authors: Mecklenburg Ingo , Sienel Wulf , Schmid Severin , Passlick Bernward , Kufer Peter
Published: April 2023

Analysis of solely bone marrow aspirates
Supplemental Table 1-4 from Overexpression of Functional SLC6A3 in Clear Cell Renal Cell Carcinoma
Authors: Hansson Jennifer , Lindgren David , Nilsson Helén , Johansson Elinn , Johansson Martin , Gustavsson Lena , Axelson Håkan
Published: April 2023

Table S1. Pathological assessment of all the primary tumors used in this paper. pT-grade = pathological tumor grade. Table S2. A list containing all TCGA samples uuids for which mRNA sequencing data was used. Table S3. Comprehensive list of all SLC and ABC transporters that were used in this study. Table S4. Results from the Limma analysis of 442 transporter genes when comparing TCGA gene expression data from 530 ccRCCs against 70 normal kidney samples.
Figure S1 from Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib
Authors: Wongchenko Matthew J. , McArthur Grant A. , Dréno Brigitte , Larkin James , Ascierto Paolo A. , Sosman Jeffrey , Andries Luc , Kockx Mark , Hurst Stephen D. , Caro Ivor , Rooney Isabelle , Hegde Priti S. , Molinero Luciana , Yue Huibin , Chang Ilsung , Amler Lukas , Yan Yibing , Ribas Antoni
Published: April 2023

Supplementary Figure S1. Flow diagram of patients providing tumor samples in each trial.
Supplementary Methods, Supplementary References, Supplementary Tables 1-2, Supplementary Figures 1-3 from Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Authors: Ballard Peter , Yates James W.T. , Yang Zhenfan , Kim Dong-Wan , Yang James Chih-Hsin , Cantarini Mireille , Pickup Kathryn , Jordan Angela , Hickey Mike , Grist Matthew , Box Matthew , Johnström Peter , Varnäs Katarina , Malmquist Jonas , Thress Kenneth S. , Jänne Pasi A. , Cross Darren
Published: April 2023

Supplementary Table S1. Osimertinib, rociletinib, and afatinib permeability across Caco2 cell Monolayers; Supplementary Table S2. Strain information; Supplementary Figure S1. Structures of osimertinib (6), its plasma metabolites AZ5104 and AZ7550, rociletinib, gefitinib, and afatinib; Supplementary Figure S2. Representative whole body autoradiogram of section through a male Lister-hooded rat at 1 hour after single oral administration of [14C]osimertinib; Supplementary Figure S3. Tumor bioluminescence in a PC9 epidermal growth factor receptor exon 19 deletion mutation-positive mouse brain metastases model during treatment with gefitinib 6.25 mg/kg once daily (QD), or vehicle.
Supplementary info from Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer
Authors: Chen Xin , Li Qiuhui , Liu Xin , Liu Can , Liu Ruifang , Rycaj Kiera , Zhang Dingxiao , Liu Bigang , Jeter Collene , Calhoun-Davis Tammy , Lin Kevin , Lu Yue , Chao Hsueh-Ping , Shen Jianjun , Tang Dean G.
Published: April 2023

Complete Supplementary Text
Fig. S5 from Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer
Authors: Chen Xin , Li Qiuhui , Liu Xin , Liu Can , Liu Ruifang , Rycaj Kiera , Zhang Dingxiao , Liu Bigang , Jeter Collene , Calhoun-Davis Tammy , Lin Kevin , Lu Yue , Chao Hsueh-Ping , Shen Jianjun , Tang Dean G.
Published: April 2023

HPCa colonies have TMPRSS2-ERG fusion.
Kaplan-Meier analysis of the survival for patients with ATL who responded to alemtuzumab therapy from Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma
Authors: Sharma Kamal , Janik John E. , O'Mahony Deirdre , Stewart Donn , Pittaluga Stefania , Stetler-Stevenson Maryalice , Jaffe Elaine S. , Raffeld Mark , Fleisher Thomas A. , Lee Cathryn C. , Steinberg Seth M. , Waldmann Thomas A. , Morris John C.
Published: April 2023

Kaplan-Meier analysis of the survival for patients with ATL who responded to alemtuzumab therapy
Supplemental Table 4 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Authors: Thompson Jeffrey C. , Yee Stephanie S. , Troxel Andrea B. , Savitch Samantha L. , Fan Ryan , Balli David , Lieberman David B. , Morrissette Jennifer D. , Evans Tracey L. , Bauml Joshua , Aggarwal Charu , Kosteva John A. , Alley Evan , Ciunci Christine , Cohen Roger B. , Bagley Stephen , Stonehouse-Lee Susan , Sherry Victoria E. , Gilbert Elizabeth , Langer Corey , Vachani Anil , Carpenter Erica L.
Published: April 2023

Summary of driver and resistance mutations in EGFR and ALK detected in ctDNA, tDNA, and both ctDNA and tDNA
Supplemental Table 3 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Authors: Thompson Jeffrey C. , Yee Stephanie S. , Troxel Andrea B. , Savitch Samantha L. , Fan Ryan , Balli David , Lieberman David B. , Morrissette Jennifer D. , Evans Tracey L. , Bauml Joshua , Aggarwal Charu , Kosteva John A. , Alley Evan , Ciunci Christine , Cohen Roger B. , Bagley Stephen , Stonehouse-Lee Susan , Sherry Victoria E. , Gilbert Elizabeth , Langer Corey , Vachani Anil , Carpenter Erica L.
Published: April 2023

All mutations detected in patient ctDNA (n=102)
Supplementary figures from Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma
Authors: Orillion Ashley , Hashimoto Ayumi , Damayanti Nur , Shen Li , Adelaiye-Ogala Remi , Arisa Sreevani , Chintala Sreenivasulu , Ordentlich Peter , Kao Chingai , Elzey Bennett , Gabrilovich Dmitry , Pili Roberto
Published: April 2023

Supplementary figures
Supplemental Table 1 from Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer
Authors: Zhao Shanshan , Geybels Milan S. , Leonardson Amy , Rubicz Rohina , Kolb Suzanne , Yan Qingxiang , Klotzle Brandy , Bibikova Marina , Hurtado-Coll Antonio , Troyer Dean , Lance Raymond , Lin Daniel W. , Wright Jonathan L. , Ostrander Elaine A. , Fan Jian-Bing , Feng Ziding , Stanford Janet L.
Published: April 2023

Number of time the 42 DNA methylation biomarkers were selected in the bootstrap samples
Supplemental Figure 5 from PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Authors: Lok Benjamin H. , Gardner Eric E. , Schneeberger Valentina E. , Ni Andy , Desmeules Patrice , Rekhtman Natasha , de Stanchina Elisa , Teicher Beverly A. , Riaz Nadeem , Powell Simon N. , Poirier John T. , Rudin Charles M.
Published: April 2023

Talazoparib and temozolomide are synergistic in vitro at two drug combination ratios (1:10,000 and 1:2,500).
Supplemental Figure 2 from PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Authors: Lok Benjamin H. , Gardner Eric E. , Schneeberger Valentina E. , Ni Andy , Desmeules Patrice , Rekhtman Natasha , de Stanchina Elisa , Teicher Beverly A. , Riaz Nadeem , Powell Simon N. , Poirier John T. , Rudin Charles M.
Published: April 2023

PARP1 expression does not predict PARP inhibitor sensitivity in SCLC. SLFN11 gene and protein expression correlate.
Supplementary Tables from Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling Pathway
Authors: Mei Qian , Li Xiang , Zhang Kang , Wu Zhiqiang , Li Xiaolei , Meng Yuanguang , Guo Mingzhou , Luo Guangbin , Fu Xiaobing , Han Weidong
Published: April 2023

Table S1. Clinicopathological characteristics of 100 cervical cancer patients Table S2. Characteristics of selected microsatellite markers Table S3. Primer sequences for miRNA quantification Table S4. Primer sequences for plasmids construction Table S5. Primer sequences for MSP analysis Table S6. Cox proportional hazards model analysis of prognostic factors in cervical cancer patients
Supplementary Tables from Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
Authors: Baltschukat Sabrina , Engstler Barbara Schacher , Huang Alan , Hao Huai-Xiang , Tam Angela , Wang Hui Qin , Liang Jinsheng , DiMare Matthew T. , Bhang Hyo-Eun Carrie , Wang Youzhen , Furet Pascal , Sellers William R. , Hofmann Francesco , Schoepfer Joseph , Tiedt Ralph
Published: April 2023

Supplementary Table 1. IC50 values for capmatinib obtained in BaF3 TRP-MET cells and mutant variants as indicated after 3-day proliferation assays with a resazurin readout. MET kinase domain mutations were either generated by site-directed mutagenesis or obtain by random mutagenesis and selection with another selective MET inhibitor (5). Supplementary Table 2. Numerical data that are graphically represented in Figure 2. Supplementary Table 3. Combined data from CCLE screens with 4 MET inhibitors (capmatinib, crizotinib, JNJ- 38877605, and PF-4217903). Related to Supplementary Fig. 1C. Supplementary Table 4. MET genomics data and additional model information for a collection of lung cancer PDX models downloaded from https://compendium.criver.com/. The Excel table is filtered down to those 66 models with complete data for MET mRNA (both Affymetrix and RNA-seq), MET mutations, and MET gene copy number, but other lung cancer models with partial data are also contained within the table. The 3 models that were used for capmatinib in vivo efficacy studies are highlighted in yellow.
supplemental figures from Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase
Authors: Kalinina Juliya , Ahn Jun , Devi Narra S. , Wang Liya , Li Yuancheng , Olson Jeffrey J. , Glantz Michael , Smith Thomas , Kim Ella L. , Giese Alf , Jensen Randy L. , Chen Clark C. , Carter Bob S. , Mao Hui , He Miao , Van Meir Erwin G.
Published: April 2023

Suppl. Figure 1. Determination of sensitivity, specificity and accuracy using ROC curves. Suppl. Figure 2. CSF levels of D-2HG and WHO grade of IDH mutant gliomas Suppl. Figure 3. CSF D-2HG levels and gender/age. Suppl. Figure 4. D- and L-2HG levels in CSF drawn at different locations in WT and mutant IDH glioma patients. Suppl. Figure 5. Comparison of NMR and MS for the detection of D-2HG in tumor tissue and CSF.
Table S1-6 from Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer
Authors: Schøler Lone V. , Reinert Thomas , Ørntoft Mai-Britt W. , Kassentoft Christine G. , Árnadóttir Sigrid S. , Vang Søren , Nordentoft Iver , Knudsen Michael , Lamy Philippe , Andreasen Ditte , Mortensen Frank V. , Knudsen Anders R. , Stribolt Katrine , Sivesgaard Kim , Mouritzen Peter , Nielsen Hans J. , Laurberg Søren , Ørntoft Torben F. , Andersen Claus L.
Published: April 2023

Supplementary Table 1 to 6
Supplementary Data from The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging
Authors: Larimer Benjamin M. , Bloch Emily , Nesti Sarah , Austin Emily E. , Wehrenberg-Klee Eric , Boland Genevieve , Mahmood Umar
Published: April 2023

Supplementary Figures and Methods
Supplementary Table 3 from AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia
Authors: Yi Xue , Sarkar Aloke , Kismali Gorkem , Aslan Burcu , Ayres Mary , Iles LaKesla R. , Keating Michael J. , Wierda William G. , Long James P. , Bertilaccio Maria Teresa Sabrina , Gandhi Varsha
Published: April 2023

Supplementary Table 3
Supplementary Material from MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB
Authors: Rose April A.N. , Annis Matthew G. , Frederick Dennie T. , Biondini Marco , Dong Zhifeng , Kwong Lawrence , Chin Lynda , Keler Tibor , Hawthorne Thomas , Watson Ian R. , Flaherty Keith T. , Siegel Peter M.
Published: April 2023

Contains supplementary methods, references and figure legends.
Supplemental Methods from MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
Authors: Dickler Maura N. , Tolaney Sara M. , Rugo Hope S. , Cortés Javier , Diéras Véronique , Patt Debra , Wildiers Hans , Hudis Clifford A. , O'Shaughnessy Joyce , Zamora Esther , Yardley Denise A. , Frenzel Martin , Koustenis Andrew , Baselga José
Published: April 2023

Methods that support the supplemental data provided
Table S1 from Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
Authors: George Daniel J. , Martini Jean-Francois , Staehler Michael , Motzer Robert J. , Magheli Ahmed , Donskov Frede , Escudier Bernard , Li Sherry , Casey Michelle , Valota Olga , Laguerre Brigitte , Pantuck Allan J. , Pandha Hardev S. , Patel Anup , Lechuga Maria , Ravaud Alain
Published: April 2023

Allele frquency
supplemental figure and table legend from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia
Authors: Pandzic Tatjana , Larsson Jimmy , He Liqun , Kundu Snehangshu , Ban Kenneth , Akhtar-Ali Muhammad , Hellström Anders R. , Schuh Anna , Clifford Ruth , Blakemore Stuart J. , Strefford Jonathan C. , Baumann Tycho , Lopez-Guillermo Armando , Campo Elias , Ljungström Viktor , Mansouri Larry , Rosenquist Richard , Sjöblom Tobias , Hellström Mats
Published: April 2023

supplemental figure and table legend
Supplementary Material and Methods from Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia
Authors: Pandzic Tatjana , Larsson Jimmy , He Liqun , Kundu Snehangshu , Ban Kenneth , Akhtar-Ali Muhammad , Hellström Anders R. , Schuh Anna , Clifford Ruth , Blakemore Stuart J. , Strefford Jonathan C. , Baumann Tycho , Lopez-Guillermo Armando , Campo Elias , Ljungström Viktor , Mansouri Larry , Rosenquist Richard , Sjöblom Tobias , Hellström Mats
Published: April 2023

Supplementary Material and Methods in Word format
Supplementary Figures 1-4 and Supplementary Tables 1-3 from Modeling the Cellular Response of Lung Cancer to Radiation Therapy for a Broad Range of Fractionation Schedules
Authors: Jeong Jeho , Oh Jung Hun , Sonke Jan-Jakob , Belderbos Jose , Bradley Jeffrey D. , Fontanella Andrew N. , Rao Shyam S. , Deasy Joseph O.
Published: April 2023

Table S1. Excluded cohorts in the analysis and the reason for exclusion; Table S2. The datasets used for this analysis in three different groups based on Mehta, et al.'s data (2012) and the estimated EQD22.8 (Gy) of the best-fit by the model simulation; Table S3. The additional datasets used for external validation of the model analysis; Figure S1. Deviations of estimated EQD210,model from BED; Figure S2. Dose-response curves estimated from maximum likelihood method based on the EQD210,model values; Figure S4. Dose-response curves obtained by applying other models to the dataset of current study: (A) Shuryak et al.'s model (69); and (B) Tai et al.'s model (70).
Table S1 from The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer
Authors: Zeng Shu-Xiong , Zhu Yanjun , Ma Ai-Hong , Yu Weimin , Zhang Hongyong , Lin Tzu-Yin , Shi Wei , Tepper Clifford G. , Henderson Paul T. , Airhart Susan , Guo Jian-Ming , Xu Chuan-Liang , deVere White Ralph W. , Pan Chong-Xian
Published: April 2023

The mutation status and absolute IC50 of bladder cancer cells
Table S1 from Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression
Authors: Gao Xiaomei , Dai Charles , Huang Shengsong , Tang Jingjie , Chen Guoyuan , Li Jianneng , Zhu Ziqi , Zhu Xuyou , Zhou Shuirong , Gao Yuanyuan , Hou Zemin , Fang Zijun , Xu Chengdang , Wang Jianyang , Wu Denglong , Sharifi Nima , Li Zhenfei
Published: April 2023

Primer sequences of genes
Figure S4 from The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer
Authors: Zeng Shu-Xiong , Zhu Yanjun , Ma Ai-Hong , Yu Weimin , Zhang Hongyong , Lin Tzu-Yin , Shi Wei , Tepper Clifford G. , Henderson Paul T. , Airhart Susan , Guo Jian-Ming , Xu Chuan-Liang , deVere White Ralph W. , Pan Chong-Xian
Published: April 2023

Ki67 and cleaved caspase 3 expression in BL0440 tumors
Supplementary Table S1 from PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors
Authors: Seifert Adrian M. , Zeng Shan , Zhang Jennifer Q. , Kim Teresa S. , Cohen Noah A. , Beckman Michael J. , Medina Benjamin D. , Maltbaek Joanna H. , Loo Jennifer K. , Crawley Megan H. , Rossi Ferdinand , Besmer Peter , Antonescu Cristina R. , DeMatteo Ronald P.
Published: April 2023

Clinicopathological features of the patients with GIST in this study.
Supplementary Data Figure 1 from Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression
Authors: Gao Xiaomei , Dai Charles , Huang Shengsong , Tang Jingjie , Chen Guoyuan , Li Jianneng , Zhu Ziqi , Zhu Xuyou , Zhou Shuirong , Gao Yuanyuan , Hou Zemin , Fang Zijun , Xu Chengdang , Wang Jianyang , Wu Denglong , Sharifi Nima , Li Zhenfei
Published: April 2023

T and DHT metabolism in MDA-Pca-2b and LAPC4 cells.
Figure S5 from In Vivo Validation of PAPSS1 (3′-phosphoadenosine 5′-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target
Authors: Leung Ada W.Y. , Veinotte Chansey J. , Melong Nicole , Oh Min Hee , Chen Kent , Enfield Katey S.S. , Backstrom Ian , Warburton Corinna , Yapp Donald , Berman Jason N. , Bally Marcel B. , Lockwood William W.
Published: April 2023

H358 spheroids with suppressed PAPSS1 expression are more sensitive to cisplatin treatment
Supplementary Material and Methods, SUpplementary Figures 1-2, Supplementary Tables 1-5, Supplementary References from Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro
Authors: Rebouissou Sandra , La Bella Tiziana , Rekik Samia , Imbeaud Sandrine , Calatayud Anna-Line , Rohr-Udilova Nataliya , Martin Yoann , Couchy Gabrielle , Bioulac-Sage Paulette , Grasl-Kraupp Bettina , de Koning Leanne , Ganne-Carrié Nathalie , Nault Jean-Charles , Ziol Marianne , Zucman-Rossi Jessica
Published: April 2023

Supplementary Figure 1. Sensitivity to selective MET inhibitors in liver cancer cell lines is related to MET gene amplification. Supplementary Figure 2. Tivantinib sensitivity is associated with high expression of genes involved in cell cycle regulation. Supplementary Table 1. Liver cancer cell lines. Supplementary Table 2. Clinical features of HCC series. Supplementary Table 3. List of the 188 genes analyzed by quantitative RT-PCR. Supplementary Table 4. Mutations and copy number variations identified in 13 genes among the 35 liver cancer cell lines (GRCh37). Supplementary Table 5. Association between tivantinib sensitivity and mutation status of the 12 most frequently mutated genes in HCC tumors and MET across the panel of 35 liver cancer cell lines.
Supplementary Table S1 from Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone
Authors: Abbasi M. Reza , Rifatbegovic Fikret , Brunner Clemens , Mann Georg , Ziegler Andrea , Pötschger Ulrike , Crazzolara Roman , Ussowicz Marek , Benesch Martin , Ebetsberger-Dachs Georg , Chan Godfrey C.F. , Jones Neil , Ladenstein Ruth , Ambros Inge M. , Ambros Peter F.
Published: April 2023

Supplementary Table S1. Tumor cell content of samples of the single neuroblastoma patient
Supplementary Figures S1-S8 from Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone
Authors: Abbasi M. Reza , Rifatbegovic Fikret , Brunner Clemens , Mann Georg , Ziegler Andrea , Pötschger Ulrike , Crazzolara Roman , Ussowicz Marek , Benesch Martin , Ebetsberger-Dachs Georg , Chan Godfrey C.F. , Jones Neil , Ladenstein Ruth , Ambros Inge M. , Ambros Peter F.
Published: April 2023

Supplementary Fig. S1: Stepwise accumulation of segmental chromosomal aberrations (SCAs) in chromosome 7 of the case study. Supplementary Fig. S2: Whole genome views of 10 different samples of a single stage 4 neuroblastoma patient. Supplementary Fig: S3: Allele difference tracks and smooth signals of chromosome 1q of four different samples of the case study. Supplementary Fig. S4: I-FISH for visualization of 1q deletion in the DTCs at diagnosis and tumor 6 at diagnosis. Supplementary Fig. S5: Frequencies of common segmental chromosomal aberrations in the DTCs with and without 1q deletions at diagnosis and relapse. Supplementary Fig. S6: Deleted regions of 19q in different patients. Supplementary Fig. S7: Event-free and overall survival curves for patients with and without 1q, 19q, or ATRX deletions in the primary tumors. Supplementary Fig. S8: Event-free and overall survival curves for patients with and without 1q, 19q, or ATRX deletions in the diagnostic DTCs.
Supplementary Table S5 from 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
Authors: D'Huyvetter Matthias , De Vos Jens , Xavier Catarina , Pruszynski Marek , Sterckx Yann G.J. , Massa Sam , Raes Geert , Caveliers Vicky , Zalutsky Michael R. , Lahoutte Tony , Devoogdt Nick
Published: April 2023

Supplementary Table S5 shows the ex vivo biodistribution of 131I-2Rs15d after 1h in mice with BT474/M1 xenografts that were pre-treated 72h earlier with a 100-fold molar excess of trastuzumab, pertuzumab or a combination of both.
Supplementary Table S1 from 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment
Authors: D'Huyvetter Matthias , De Vos Jens , Xavier Catarina , Pruszynski Marek , Sterckx Yann G.J. , Massa Sam , Raes Geert , Caveliers Vicky , Zalutsky Michael R. , Lahoutte Tony , Devoogdt Nick
Published: April 2023

Supplementary Table S1 shows the X-ray crystallographic data collection and refinement statistics.
Supplementary Data from IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System
Authors: Puig-Saus Cristina , Parisi Giulia , Garcia-Diaz Angel , Krystofinski Paige E. , Sandoval Salemiz , Zhang Ruixue , Champhekar Ameya S. , McCabe James , Cheung-Lau Gardenia C. , Truong Nhat A. , Vega-Crespo Agustin , Komenan Marie Desiles S. , Pang Jia , Macabali Mignonette H. , Saco Justin D. , Goodwin Jeffrey L. , Bolon Brad , Seet Christopher S. , Montel-Hagen Amelie , Crooks Gay M. , Hollis Roger P. , Campo-Fernandez Beatriz , Bischof Daniela , Cornetta Kenneth , Gschweng Eric H. , Adelson Celia , Nguyen Alexander , Yang Lili , Witte Owen N. , Baltimore David , Comin-Anduix Begonya , Kohn Donald B. , Wang Xiaoyan , Cabrera Paula , Kaplan-Lefko Paula J. , Berent-Maoz Beata , Ribas Antoni
Published: April 2023

Supplemental Figure 1: Hypothetical model of peripheral blood TCR-transgenic cell repopulation. Supplemental Figure 2: GLP team organizational chart. Supplemental Figure 3. Bone marrow transplant (BMT) optimization studies in HLA-A2/Kb transgenic mice. Supplemental Figure 4. Body weight and hematology assessment at day 5 and 3 months after BMT. Supplemental Figure 5. Spleen and bone marrow cellularity at day 5 and 3 months after BMT. Supplemental Figure 6. Serum chemistry at 3 months after BMT. Supplemental Figure 7. Flow cytometry gating strategy for bone marrow and splenocytes phenotype characterization. Supplemental Figure 8. Survival and hematology 3 months after BMT with Lin- cells transduced with LV-empty, LV-NY-ESO-1 TCR or LV-NY-ESO-1 TCR/sr39TK. Supplemental Figure 9. Differentiation of NYESO TCR/sr39TK-engineered T cells in ATOs (artificial thymic organoids). Supplemental Table 1. Certificate of Analysis of the GMP-comparable LV-NY-ESO-1 TCR/sr39TK (RRL-MSCV-optNYESO-optsr39TK-WPRE, production volume: 20L). Supplemental Table 2. Certificate of Analysis of the Clinical Grade Lentivirus LV-NY-ESO- 1 TCR/sr39TK (RRL-MSCV-optNYESO-optsr39TK-WPRE, production volume 60L). Supplemental Table 3. Certificate of Analysis of the clinical grade RV-NY-ESO-1 TCR (MSGV1-A2aB-1G4A-LY3H10) (Production volume 18L)*. Supplemental Table 4. Certificate of Analysis of the GMP comparable RV-NY-ESO-1 TCR (MSGV1-A2ab-1G4A-Ly3H10, Production volume: 3L). Supplemental Table 5. Co-Administration of NY-ESO-1 TCR Genetically Modified T cells and Hematopoietic Stem Cells (HSCs) in HLA-A2.1/Kb mice. GLP studies cohort distribution. Supplemental Table 6. Cell manufacturing acceptance criteria. Supplemental Table 7. List of protocol-specific organs. Supplemental Table 8. Manufacturing validation runs. Supplemental Table 9. Comparison between fresh and cryopreserved product at 1, 30, 90 and 180# days.
Supplementary Tables S1 - S3 from Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters
Authors: Pakish Janelle B. , Zhang Qian , Chen Zhongyuan , Liang Han , Chisholm Gary B. , Yuan Ying , Mok Samuel C. , Broaddus Russell R. , Lu Karen H. , Yates Melinda S.
Published: April 2023

Supplementary Tables include: Supplementary Table S1. Fluorescent IHC multiplexing antibodies and conditions. Supplementary Table S2. Summary of Lynch syndrome testing characteristics for cases included in LS MSI-H EC analysis. Supplementary Table S3. Clinicopathological characteristics by MSI-H subgroup.
Figure S6 from Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation
Authors: Shi Puyu , Oh You-Take , Deng Liang , Zhang Guojing , Qian Guoqing , Zhang Shuo , Ren Hui , Wu Grant , Legendre Benjamin , Anderson Emily , Ramalingam Suresh S. , Owonikoko Taofeek K. , Chen Mingwei , Sun Shi-Yong
Published: April 2023

The combination of AZD9291 with a MEK inhibitor effectively inhibits the growth of PC-9/3M cells
Figure S1 from Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation
Authors: Shi Puyu , Oh You-Take , Deng Liang , Zhang Guojing , Qian Guoqing , Zhang Shuo , Ren Hui , Wu Grant , Legendre Benjamin , Anderson Emily , Ramalingam Suresh S. , Owonikoko Taofeek K. , Chen Mingwei , Sun Shi-Yong
Published: April 2023

Establishment of AZD9291-resistant cell lines from PC-9 or PC9-GR cells (A and B) and detection of EGFR T797S mutation (C)
Table S3 from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer
Authors: Liu Li , Bai Xue , Wang Jian , Tang Xin-Ran , Wu De-Hua , Du Sha-Sha , Du Xiu-Ju , Zhang Yao-Wei , Zhu Hong-Bo , Fang Yuan , Guo Ze-Qin , Zeng Qin , Guo Xue-Jun , Liu Zhu , Dong Zhong-Yi
Published: April 2023

Univariate and Multivariable Cox regression analysis of predictive factors in two cohorts treated with immune checkpoint inhibitors.
Table S2 from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer
Authors: Liu Li , Bai Xue , Wang Jian , Tang Xin-Ran , Wu De-Hua , Du Sha-Sha , Du Xiu-Ju , Zhang Yao-Wei , Zhu Hong-Bo , Fang Yuan , Guo Ze-Qin , Zeng Qin , Guo Xue-Jun , Liu Zhu , Dong Zhong-Yi
Published: April 2023

Multivariate analysis of clinical and genetic features associated with overall survival in 8 cancer types of MSK pan-cancer cohort.
Supplementary Table S1 from Anticancer effects of tanshinone I in human non-small cell lung cancer
Authors: Lee Chen-Yu , Sher Hui-Fang , Chen Huei-Wen , Liu Chun-Chi , Chen Ching-Hsien , Lin Choun-Sea , Yang Pan-Chyr , Tsay Hsin-Sheng , Chen Jeremy J.W.
Published: April 2023

Supplementary Table S1 from Anticancer effects of tanshinone I in human non-small cell lung cancer
Supplementary Fig. S2 from Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
Authors: Lang Sven A. , Schachtschneider Philipp , Moser Christian , Mori Akira , Hackl Christina , Gaumann Andreas , Batt David , Schlitt Hans J. , Geissler Edward K. , Stoeltzing Oliver
Published: April 2023

Supplementary Fig. S2 from Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes
Supplementary Fig. S1 from Monoclonal antibody 14C5 targets integrin αvβ5
Authors: Burvenich Ingrid , Schoonooghe Steve , Vervoort Liesbet , Dumolyn Caroline , Coene Elisabeth , Vanwalleghem Lieve , Van Huysse Jacques , Praet Marleen , Cuvelier Claude , Mertens Nico , De Vos Filip , Slegers Guido
Published: April 2023

Supplementary Fig. S1 from Monoclonal antibody 14C5 targets integrin αvβ5
Supplementary Figure 3 from Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells
Authors: Hage-Sleiman Rouba , Herveau Stéphanie , Matera Eva-Laure , Laurier Jean-Fabien , Dumontet Charles
Published: April 2023

Supplementary Figure 3 from Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells
Supplementary Table 2 from Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
Authors: Dalle Stephane , Reslan Lina , Besseyre de Horts Timothee , Herveau Stephanie , Herting Frank , Plesa Adriana , Friess Thomas , Umana Pablo , Klein Christian , Dumontet Charles
Published: April 2023

XLS - 25K, Supplementary Table 2
Supplementary Data from Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines
Authors: Zajac Magdalena , Moneo Maria Victoria , Carnero Amancio , Benitez Javier , Martínez-Delgado Beatriz
Published: April 2023

Supplementary Data from Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines
Supplementary Figures 4-5 from Anticancer Activity of a Combination of Cisplatin and Fisetin in Embryonal Carcinoma Cells and Xenograft Tumors
Authors: Tripathi Rakshamani , Samadder Tanmoy , Gupta Sarika , Surolia Avadhesha , Shaha Chandrima
Published: April 2023

Supplementary Figures 4-5 from Anticancer Activity of a Combination of Cisplatin and Fisetin in Embryonal Carcinoma Cells and Xenograft Tumors
Supplementary Fig. S1 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Authors: Gonzales Andrea J. , Hook Kenneth E. , Althaus Irene W. , Ellis Paul A. , Trachet Erin , Delaney Amy M. , Harvey Patricia J. , Ellis Teresa A. , Amato Danielle M. , Nelson James M. , Fry David W. , Zhu Tong , Loi Cho-Ming , Fakhoury Stephen A. , Schlosser Kevin M. , Sexton Karen E. , Winters R. Thomas , Reed Jessica E. , Bridges Alex J. , Lettiere Daniel J. , Baker Deborah A. , Yang Jianxin , Lee Helen T. , Tecle Haile , Vincent Patrick W.
Published: April 2023

Supplementary Fig. S1 from Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Supplementary Figures 2-3 from Anticancer Activity of a Combination of Cisplatin and Fisetin in Embryonal Carcinoma Cells and Xenograft Tumors
Authors: Tripathi Rakshamani , Samadder Tanmoy , Gupta Sarika , Surolia Avadhesha , Shaha Chandrima
Published: April 2023

Supplementary Figures 2-3 from Anticancer Activity of a Combination of Cisplatin and Fisetin in Embryonal Carcinoma Cells and Xenograft Tumors
Supplementary Table S5 from Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy
Authors: Su David M. , Zhang Qiuyang , Wang Xuexi , He Ping , Zhu Yuelin Jack , Zhao Jianxiong , Rennert Owen M. , Su Yan A.
Published: April 2023

Supplementary Table S5 from Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy
Supplementary Fig. S2 from Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage
Authors: Krynetskaia Natalia F. , Phadke Manali S. , Jadhav Sachin H. , Krynetskiy Evgeny Y.
Published: April 2023

Supplementary Fig. S2 from Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage
Supplementary Fig. S1 from Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage
Authors: Krynetskaia Natalia F. , Phadke Manali S. , Jadhav Sachin H. , Krynetskiy Evgeny Y.
Published: April 2023

Supplementary Fig. S1 from Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage
Supplementary Table S3 from Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy
Authors: Su David M. , Zhang Qiuyang , Wang Xuexi , He Ping , Zhu Yuelin Jack , Zhao Jianxiong , Rennert Owen M. , Su Yan A.
Published: April 2023

Supplementary Table S3 from Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy
Supplementary Table S1 from Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy
Authors: Su David M. , Zhang Qiuyang , Wang Xuexi , He Ping , Zhu Yuelin Jack , Zhao Jianxiong , Rennert Owen M. , Su Yan A.
Published: April 2023

Supplementary Table S1 from Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy
Supplementary Fig. S2 from Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy
Authors: Su David M. , Zhang Qiuyang , Wang Xuexi , He Ping , Zhu Yuelin Jack , Zhao Jianxiong , Rennert Owen M. , Su Yan A.
Published: April 2023

Supplementary Fig. S2 from Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy
Supplementary Fig. S4 from Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor
Authors: Abouantoun Thamara J. , MacDonald Tobey J.
Published: April 2023

Supplementary Fig. S4 from Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor
Supplementary Fig. S3 from Dehydrocostuslactone disrupts signal transducers and activators of transcription 3 through up-regulation of suppressor of cytokine signaling in breast cancer cells
Authors: Kuo Po-Lin , Ni Wen-Chiu , Tsai Eing-Mei , Hsu Ya-Ling
Published: April 2023

Supplementary Fig. S3 from Dehydrocostuslactone disrupts signal transducers and activators of transcription 3 through up-regulation of suppressor of cytokine signaling in breast cancer cells
Supplementary Table 2 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Authors: Weisberg Ellen , Choi Hwan Geun , Barrett Rosemary , Zhou Wenjun , Zhang Jianming , Ray Arghya , Nelson Erik A. , Jiang Jingrui , Moreno Daisy , Stone Richard , Galinsky Ilene , Fox Edward , Adamia Sophia , Kung Andrew L. , Gray Nathanael S. , Griffin James D.
Published: April 2023

Supplementary Table 2 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Supplementary Video 1 from Endocytosis of PEGylated Agents Enhances Cancer Imaging and Anticancer Efficacy
Authors: Chuang Kuo-Hsiang , Wang Hsin-Ell , Chen Fang-Ming , Tzou Shey-Cherng , Cheng Chiu-Min , Chang Ya-Chen , Tseng Wei-Lung , Shiea Jentaie , Lin Shiu-Ru , Wang Jaw-Yuan , Chen Bing-Mae , Roffler Steve R. , Cheng Tian-Lu
Published: April 2023

Supplementary Video 1 from Endocytosis of PEGylated Agents Enhances Cancer Imaging and Anticancer Efficacy
Supplementary Data from Targeting NF-κB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer
Authors: Li Bin , Li Yuk Yin , Tsao Sai Wah , Cheung Annie L.M.
Published: April 2023

Supplementary Data from Targeting NF-κB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer
Supplementary Figure 8 from GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
Authors: Sabbatini Peter , Korenchuk Susan , Rowand Jason L. , Groy Arthur , Liu Qi , Leperi Dominic , Atkins Charity , Dumble Melissa , Yang Jingsong , Anderson Kelly , Kruger Ryan G. , Gontarek Richard R. , Maksimchuk Kenneth R. , Suravajjala Sapna , Lapierre Russell R. , Shotwell J. Brad , Wilson Joseph W. , Chamberlain Stanley D. , Rabindran Sridhar K. , Kumar Rakesh
Published: April 2023

Supplementary Figure 8. Effect of GSK1838705A on ALK signaling in vitro.